Botaneco Announces Launch of Second Generation Oleosome Product

Calgary, Canada (ots/PRNewswire) -

- Natural Hydresia(TM) G2 Offers Enhanced Formulation Flexibility
With a Globally Accepted Preservative System

Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc.
(TSX: SBS), focused on the development and commercialization of
oleosome technology in personal care, OTC and topical pharmaceutical
markets, today announced the launch of its second generation
oleosome product, Hydresia(TM ) G2, at the In-Cosmetics 2008
exposition in Amsterdam. Hydresia(TM) G2, a natural emulsion base,
retains all of the functional performance properties of Botaneco's
first generation Hydresia(TM) product, while offering formulators
the ability to develop products over a broader pH range (3.5- 8.5).
This will allow for the development of low pH exfoliants and anti-
aging products that can provide consumers with the moisturization,
skin health and aesthetic benefits that Hydresia(TM) brings to other
finished formulations. In addition, Hydresia(TM) G2 uses a new
globally accepted preservative system that will expand the use of
oleosomes in European and other markets.

"Botaneco is committed to developing ingredients that allow our
customers to provide differentiated products that offer both
performance and aesthetic benefits to consumers," said Andrew Baum,
President and CEO of Botaneco's parent company, SemBioSys.
"Hydresia(TM) G2 can be used in moisturizers, hair and skin
cleansers, lip care, color cosmetics, skin lighteners, sun care and
baby care products just like our first generation Hydresia(TM)
product. In addition to these applications, Hydresia(TM) G2 can
also be used in products where requirements for low pH have precluded
the use of Hydresia(TM). We are excited about the opportunity to
expand our product offerings in North America, as well as expanding
into European and Asian markets."

Hydresia(TM) G2, as well as the first generation Hydresia(TM)
product, each allow cosmetic and health care formulators to develop
new products using "cold-processing" which reduces formulation and
processing time by an order of magnitude.

Botaneco's proprietary Hydresia and Hydresia(TM) G2 products are
natural emulsifiers comprised of oleosomes, natural oil carrying
structures derived from safflower seeds. Oleosomes are nature's
warehouse, or storage facility, for the emollient oils, antioxidants
and natural moisture barriers that serve to keep the skin soft,
supple and young looking. Using a proprietary non-solvent aqueous
extraction process, these oleosomes are isolated from the seed fully
intact, and when used in skin care applications can provide lasting
protection to the skin. Hydresia(TM) and Hydresia(TM) G2 are
natural, renewable replacements for hydrocarbon derived petrolatum,
mineral oil and non-ionic surfactants.

About Botaneco

Botaneco is the global developer and marketer of innovative
oleosome- based ingredients to the personal care and OTC topical
markets. As a technologically driven provider of high performance,
proprietary oleosome based ingredients, Botaneco is committed to
developing groundbreaking ingredients that offer multifunctional,
tangible and documented benefits to both formulators and consumers.
Botaneco's manufacturing facility is located in Calgary, Canada
while its sales and marketing and research and development
laboratories are in Bensalem PA.

More information is available and can be accessed at
http://www.botaneco.ca.

About SemBioSys (TSX:SBS)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology
company developing protein-based pharmaceuticals for metabolic and
cardiovascular diseases. The Company's lead pharmaceutical
candidates, produced in the plant host safflower, are recombinant
human insulin, to serve the rapidly expanding global diabetes market
and Apo AI, a next generation cardiovascular drug. In addition to its
pharmaceutical products, SemBioSys is developing a series of
non-pharmaceutical products addressing human topical, nutritional
oils and agricultural biotechnology markets. More information is
available and can be accessed at http://www.sembiosys.com.

This press release contains certain forward-looking statements,
including, without limitation, statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and other similar expressions which
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. Forward-looking statements
reflect the Company's current expectation and assumptions, and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including,
but not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory approval
process and other risks detailed from time-to-time in the Company's
ongoing filings with the Canadian securities regulatory authorities
which filings can be found at http://www.sedar.com. Given these risks
and uncertainties, readers are cautioned not to place undue reliance
on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or
otherwise, except as required by applicable Canadian securities laws.

ots Originaltext: Botaneco and SemBioSys Genetics Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media and Business Contact: Andrew Baum, Botaneco, Ph:
+1-403-717-8751, Fax: +1-403-250-3886, Email: bauma@sembiosys.com,
Internet: http://www.botaneco.ca